Status: Recruiting
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.
Participants needed: 600
Trial details
Phase: Phase 1Age: 18-99Biological sex: AllType: InterventionalSponsor: Erasca, Inc.Updated: Jun 26, 2026Locations: 7
Eligibility criteria
Age ≥ 18 years [+7]
Previous treatment with a RAS inhibitor [+6]